Sanofi-GSK Covid-19 vaccine triggers immune responses in trial
A Covid-19 vaccine developed by Sanofi and GSK triggers immune responses in people aged 18 years and above in Phase II trial.
Liquid biopsy tech: non-invasive cancer monitoring in clinical trials
Liquid biopsy company Angle recently secured its first large-scale pharma services contract. Clinical Trials Arena...
Noxopharm closes enrolment in Veyonda’s Covid-19 trial
Noxopharm has completed enrolment in the Phase I NOXCOVID study of Veyonda against Covid-19.
Altimmune’s intranasal Covid-19 vaccine shows sterilising immunity
In a SARS-CoV-2 challenge model, a single dose of the vaccine delivered sterilising immunity in the lungs of mice, while...
Brave new world: trialling VR to ease pain and stress
Virtual reality has shown the potential to help patients deal with pain and anxiety during difficult procedures and clinical trials....
Latest Deals
-
EmmesMergers & Acquisitions Undisclosed
-
Science 37Mergers & Acquisitions Undisclosed
-
EmmesMergers & Acquisitions Undisclosed
-
Science 37Mergers & Acquisitions Undisclosed
Weekly chart
Countries administering the most Covid-19 vaccine doses so far
Top ten countries by Covid-19 vaccine doses administered to date (numbers in millions)
| Country | Millions of doses |
|---|---|
| China | 324.3 |
| United States | 259.7 |
| India | 168.3 |
| United Kingdom | 53 |
| Brazil | 46.9 |
| Germany | 34.4 |
| France | 25.4 |
| Turkey | 24.9 |
| Italy | 24 |
| Indonesia | 22 |
Latest News
Poll finds independent verification of ESG disclosures to be important
Verification by independent auditors ensures that a company’s financial and non-financial data is accurate. It helps in filling the gap…
Magenta’s multiple myeloma treatment trial meets primary endpoint
Magenta Therapeutics has reported that Phase II clinical trial of MGTA-145 in combination with plerixafor in multiple myeloma patients met…
Exscientia’s third AI-discovered molecule to enter trials
Oxford-based pharmatech company Exscientia has announced that its third clinical molecule created using artificial intelligence (AI) is set to enter…
Emmes acquires rare diseases CRO Orphan Reach
Global clinical research organisation (CRO) Emmes has acquired UK-based rare diseases CRO Orphan Reach to boost its research base for…
Latest Themes
AI and Covid’s symbiotic relationship may make for tech’s Trojan horse
With AI more than rising to the challenge of Covid-19, its spread throughout the business ecosphere will only be a matter of time – and...
THREAD Q&A: bridging the gap between patients and trials with social media
THREAD, a tech-focused service provider that enables decentralised clinical trials, has recently penned a partnership with CureClick, a community-powered platform that harnesses social media influencers...
Akili presents more positive trial data for ADHD gaming therapy
Akili Interactive has published data from its STARS-Adjunct trial supporting the efficacy of EndeavorRx, its attention-deficit hyperactivity disorder (ADHD) video game therapy for kids, in...
MHRA pilot aims to boost patient involvement in clinical research
In a bid to put patient involvement at the heart of drug development and clinical trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has...
ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving at a matching pace. Clinical...
Q&A with N-SIDE’s Sébastien Coppe: how digitisation overcomes clinical bottlenecks
The Covid-19 pandemic has transformed clinical development. Rather than taking ten years to bring a drug to market, vaccine manufacturers showed a drug can be...
Telemedicine to benefit the most from remote patient monitoring tools: Poll
The COVID-19 pandemic has led to a surge in the use of remote patient monitoring (RPM) tools to monitor patients outside the standard healthcare settings.
Companies seek to improve operational efficiency with digital transformation: Survey
The COVID-19 pandemic triggered unexpected challenges in the business environment prompting pharmaceutical companies to accelerate the adoption of digital transformation strategies.
Expert Commentary & Analysis
View MoreLoA Update: United Therapeutics’ Unituxin for osteosarcoma tumbles 12 points in FDA regulatory potential after NCI-sponsored Phase II results
As of 11 May, the Likelihood of Approval (LoA) for United Therapeutics’ (NASDAQ:UTHR) Unituxin (dinutuximab) for osteosarcoma dropped 12 points, according to GlobalData’s LoA data. This news is the result…
Pfizer/BioNTech’s Covid-19 vaccine mega deal ousts AstraZeneca from EU; Moderna, J&J best positioned for more preorders but minimal
Moderna’s tech, J&J single-dose administration are selling points Legal battle, side effects an obstacle for further AstraZeneca deals Direct-to-manufacturer arrangement probable but limited rewards Moderna and Johnson & Johnson still…
CKD-HPT, HP and HK market estimated to grow by CAGR of 6.9%
With pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the chronic kidney disease-hyperparathyroidism (CKD-HPT), hyperphosphatemia (HP) and hyperkalemia (HK) market is expected to grow at a…
Comirnaty for teens will bring US closer to herd immunity and increase Pfizer’s market share
On May 10, the US Food and Drug Administration (FDA) authorised Pfizer and BioNTech’s Covid-19 vaccine Comirnaty for adolescents aged 12 to 15 years. The decision was confirmed by the…